FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042203003> ?p ?o ?g. }

• W2042203003 endingPage "1387" @default.
• W2042203003 startingPage "1374" @default.
• W2042203003 abstract "Objectives.— To evaluate the long‐term safety, tolerability, effectiveness, impact on quality of life, and medication satisfaction of sumatriptan/naproxen sodium in the acute treatment of migraine headache in adolescents. Methods.— This 12‐month, multicenter, open‐label, safety study was conducted in adolescents (aged 12‐17 years) with an average of 2‐8 migraines/month typically lasting >2 hours untreated for >6 months prior to initiation. Subjects were instructed to treat migraines as early as possible and were allowed to rescue 2 hours post dose with a single dose of a naproxen‐containing product, over‐the‐counter pain reliever, or anti‐emetics. Subjects were advised not to take a second tablet of sumatriptan/naproxen sodium without at least a 24‐hour headache‐free period. Safety evaluations included adverse events, laboratory tests, and vital signs and electrocardiogram evaluation. Other evaluations included freedom from pain, quality of life, and medication satisfaction. Results.— Of the 656 subjects enrolled, 622 (95%) treated at least 1 migraine with sumatriptan/naproxen sodium, of which 435 (70%) and 363 (58%) completed 6 and 12 months of the study, respectively. Overall, there were 12,927 exposures to sumatriptan/naproxen sodium: on average 2.5 tablets were taken per month per subject. The most common treatment‐related adverse events were nausea (7%), dizziness (3%), muscle tightness (3%), and chest discomfort (3%). There were no deaths; 4 subjects had 5 serious adverse events (suicide attempt, hemolytic anemia and syncope, suicidal ideation, spontaneous abortion) unrelated to sumatriptan/naproxen sodium and resolved without sequelae. Seven percent of subjects discontinued participation in the study because of an adverse event; 5% of subjects discontinued due to lack of efficacy. Overall, 42% of the migraine attacks were pain‐free within 2 hours of treatment with sumatriptan/naproxen sodium, subjects reported improvements from baseline in 2 of 3 quality of life domains over time, and were generally satisfied with the efficacy and overall treatment at the end of the study. Conclusion.— In adolescent migraineurs, after up to 12 months and over 12,000 exposures to sumatriptan/naproxen sodium, there were no new or clinically significant findings in the safety parameters, including the frequency and nature of adverse events, as compared to the individual components or to the adverse event profile in adults. In addition, sumatriptan/naproxen sodium provided freedom from pain over time, improvements in quality of life and medication satisfaction." @default.
• W2042203003 created "2016-06-24" @default.
• W2042203003 creator A5006365150 @default.
• W2042203003 creator A5020607799 @default.
• W2042203003 creator A5025391686 @default.
• W2042203003 creator A5044293820 @default.
• W2042203003 creator A5059903481 @default.
• W2042203003 creator A5067329770 @default.
• W2042203003 creator A5073962544 @default.
• W2042203003 creator A5076542952 @default.
• W2042203003 creator A5085795028 @default.
• W2042203003 creator A5087172990 @default.
• W2042203003 date "2011-07-28" @default.
• W2042203003 modified "2023-10-17" @default.
• W2042203003 title "Long-Term Evaluation of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents" @default.
• W2042203003 cites W1965827615 @default.
• W2042203003 cites W1975675690 @default.
• W2042203003 cites W1993165855 @default.
• W2042203003 cites W1994172792 @default.
• W2042203003 cites W1995175988 @default.
• W2042203003 cites W2000724197 @default.
• W2042203003 cites W2000729578 @default.
• W2042203003 cites W2003163400 @default.
• W2042203003 cites W2004013725 @default.
• W2042203003 cites W2019546364 @default.
• W2042203003 cites W2022293527 @default.
• W2042203003 cites W2022884444 @default.
• W2042203003 cites W2028683954 @default.
• W2042203003 cites W2039874384 @default.
• W2042203003 cites W2041898141 @default.
• W2042203003 cites W2051283521 @default.
• W2042203003 cites W2055064537 @default.
• W2042203003 cites W2060756080 @default.
• W2042203003 cites W2066537633 @default.
• W2042203003 cites W2068520581 @default.
• W2042203003 cites W2072534931 @default.
• W2042203003 cites W2080914233 @default.
• W2042203003 cites W2116593011 @default.
• W2042203003 cites W2140441002 @default.
• W2042203003 cites W2146835163 @default.
• W2042203003 cites W2156439264 @default.
• W2042203003 cites W2169042796 @default.
• W2042203003 cites W2288605373 @default.
• W2042203003 cites W4251165208 @default.
• W2042203003 cites W2280140377 @default.
• W2042203003 doi "https://doi.org/10.1111/j.1526-4610.2011.01965.x" @default.
• W2042203003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21797863" @default.
• W2042203003 hasPublicationYear "2011" @default.
• W2042203003 type Work @default.
• W2042203003 sameAs 2042203003 @default.
• W2042203003 citedByCount "32" @default.
• W2042203003 countsByYear W20422030032012 @default.
• W2042203003 countsByYear W20422030032013 @default.
• W2042203003 countsByYear W20422030032014 @default.
• W2042203003 countsByYear W20422030032015 @default.
• W2042203003 countsByYear W20422030032016 @default.
• W2042203003 countsByYear W20422030032017 @default.
• W2042203003 countsByYear W20422030032018 @default.
• W2042203003 countsByYear W20422030032019 @default.
• W2042203003 countsByYear W20422030032020 @default.
• W2042203003 countsByYear W20422030032021 @default.
• W2042203003 countsByYear W20422030032022 @default.
• W2042203003 countsByYear W20422030032023 @default.
• W2042203003 crossrefType "journal-article" @default.
• W2042203003 hasAuthorship W2042203003A5006365150 @default.
• W2042203003 hasAuthorship W2042203003A5020607799 @default.
• W2042203003 hasAuthorship W2042203003A5025391686 @default.
• W2042203003 hasAuthorship W2042203003A5044293820 @default.
• W2042203003 hasAuthorship W2042203003A5059903481 @default.
• W2042203003 hasAuthorship W2042203003A5067329770 @default.
• W2042203003 hasAuthorship W2042203003A5073962544 @default.
• W2042203003 hasAuthorship W2042203003A5076542952 @default.
• W2042203003 hasAuthorship W2042203003A5085795028 @default.
• W2042203003 hasAuthorship W2042203003A5087172990 @default.
• W2042203003 hasConcept C126322002 @default.
• W2042203003 hasConcept C142724271 @default.
• W2042203003 hasConcept C170493617 @default.
• W2042203003 hasConcept C197934379 @default.
• W2042203003 hasConcept C204787440 @default.
• W2042203003 hasConcept C2778115740 @default.
• W2042203003 hasConcept C2778375690 @default.
• W2042203003 hasConcept C2778541695 @default.
• W2042203003 hasConcept C2778871607 @default.
• W2042203003 hasConcept C2778938600 @default.
• W2042203003 hasConcept C2780580376 @default.
• W2042203003 hasConcept C2909752691 @default.
• W2042203003 hasConcept C42219234 @default.
• W2042203003 hasConcept C71924100 @default.
• W2042203003 hasConceptScore W2042203003C126322002 @default.
• W2042203003 hasConceptScore W2042203003C142724271 @default.
• W2042203003 hasConceptScore W2042203003C170493617 @default.
• W2042203003 hasConceptScore W2042203003C197934379 @default.
• W2042203003 hasConceptScore W2042203003C204787440 @default.
• W2042203003 hasConceptScore W2042203003C2778115740 @default.
• W2042203003 hasConceptScore W2042203003C2778375690 @default.
• W2042203003 hasConceptScore W2042203003C2778541695 @default.
• W2042203003 hasConceptScore W2042203003C2778871607 @default.
• W2042203003 hasConceptScore W2042203003C2778938600 @default.

• next